Daily Endocrinology Research Analysis
A 16-week randomized controlled trial shows time-restricted eating (TRE) reduces hepatic steatosis in MASLD comparably to calorie restriction with good tolerability. A phase 3 randomized trial in Chinese statin-intolerant patients demonstrates the PCSK9 monoclonal antibody ongericimab reduces LDL-C by ~66% with a safety profile similar to placebo. A longitudinal cohort of ~196,000 Japanese adults validates composite obesity–lipid indices (AIP, CMI, LAP) as strong predictors of incident type 2 di
Summary
A 16-week randomized controlled trial shows time-restricted eating (TRE) reduces hepatic steatosis in MASLD comparably to calorie restriction with good tolerability. A phase 3 randomized trial in Chinese statin-intolerant patients demonstrates the PCSK9 monoclonal antibody ongericimab reduces LDL-C by ~66% with a safety profile similar to placebo. A longitudinal cohort of ~196,000 Japanese adults validates composite obesity–lipid indices (AIP, CMI, LAP) as strong predictors of incident type 2 diabetes.
Research Themes
- Lifestyle interventions for metabolic liver disease
- Lipid-lowering biologics in statin-intolerant patients
- Risk prediction for incident type 2 diabetes using composite obesity–lipid indices
Selected Articles
1. Efficacy and safety of time-restricted eating in metabolic dysfunction-associated steatotic liver disease.
In a 16-week three-arm RCT (n=333), TRE reduced hepatic steatosis by 25.8% versus 0.7% with standard care (p<0.001), achieving similar reductions as calorie restriction (−24.7%; p>0.999). TRE also led to greater reductions in body weight, waist circumference, and fat mass than standard care, with no differences versus calorie restriction, and no serious adverse events.
Impact: Provides randomized evidence that TRE is as effective as calorie restriction for reducing liver fat in MASLD, offering a pragmatic dietary strategy with good safety.
Clinical Implications: TRE can be considered as an alternative to calorie restriction for short-term reduction of hepatic steatosis in MASLD, with similar metabolic benefits and acceptable safety. Long-term adherence and histological outcomes remain to be established.
Key Findings
- TRE reduced hepatic steatosis by −25.8% vs standard of care 0.7% (p<0.001).
- TRE achieved similar hepatic fat reduction as calorie restriction (−24.7%; p>0.999).
- TRE led to greater reductions in body weight, waist circumference, and fat mass versus standard care.
- Liver stiffness, glucose homeostasis, and sleep quality changes were comparable between TRE and calorie restriction.
- No serious adverse events were reported.
Methodological Strengths
- Randomized, three-arm design with active comparator (calorie restriction) and MRI-PDFF primary endpoint.
- Adequate sample size (n=333) with pre-registration and safety monitoring; full analysis set used.
Limitations
- Short intervention duration (16 weeks) without histological confirmation.
- Open-label dietary interventions may introduce performance bias; generalizability beyond study population uncertain.
Future Directions: Assess long-term adherence, histological endpoints, and cardiometabolic outcomes; evaluate TRE in diverse MASLD phenotypes and in combination with pharmacotherapies.
BACKGROUND & AIMS: Time-restricted eating (TRE) may improve weight loss, insulin resistance, and body composition, which are key factors in the pathophysiology of metabolic dysfunction-associated steatotic liver disease (MASLD). However, evidence on the efficacy of TRE in patients with MASLD is limited. This study aimed to evaluate the potential benefits of TRE in patients with overweight or obesity and MASLD. METHODS: In this 16-week randomized controlled trial, patients with overweight or obesity and MASLD were randomized into three groups in a 1:1:1 ratio: standard of care (SOC), calorie restri
2. Efficacy and safety of ongericimab in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, placebo-controlled phase 3 trial.
In 139 statin-intolerant Chinese adults, ongericimab reduced LDL-C by an LS mean 66.2% versus placebo at week 12 (p<0.0001), with sustained reductions through week 52. Non-HDL-C, ApoB, total cholesterol, and Lp(a) also decreased significantly, and overall adverse event rates were comparable to placebo.
Impact: Delivers rigorous, population-specific phase 3 evidence for a novel PCSK9 mAb in statin-intolerant patients, addressing an important therapeutic gap.
Clinical Implications: Ongericimab is a potent LDL-lowering option for statin-intolerant patients; clinicians may consider it when LDL-C goals are unmet with non-statin therapies. Outcome trials are needed to confirm cardiovascular benefit.
Key Findings
- LDL-C LS mean reduction vs placebo at week 12: −66.2% (95% CI −74.2% to −58.2%; p<0.0001).
- Reductions in non-HDL-C, ApoB, total cholesterol, and Lp(a) were significant.
- LDL-C reductions were sustained through week 52 in the open-label period.
- Overall incidence of treatment-emergent adverse events was comparable between groups.
Methodological Strengths
- Randomized, multicenter, double-blind, placebo-controlled phase 3 design.
- Prespecified lipid endpoints with sustained follow-up to 52 weeks.
Limitations
- Double-blind period was 12 weeks; cardiovascular outcomes were not assessed.
- Population limited to Chinese statin-intolerant patients; generalizability may be restricted.
Future Directions: Conduct cardiovascular outcomes trials, comparative effectiveness studies vs other PCSK9 inhibitors or inclisiran, and long-term safety/cost-effectiveness assessments.
BACKGROUND AND AIMS: Several protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to significantly reduce low-density lipoprotein cholesterol (LDL-C) levels in statin-intolerant patients, but none have been verified in Chinese patients. This study aimed to evaluate the efficacy and safety of ongericimab, a novel PCSK9 monoclonal antibody, in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia. METHODS: This was a randomized, multicenter, doubl
3. Predictive value of obesity-related indices for incident type 2 diabetes mellitus: a longitudinal study of the Fukushima Health Database 2015-2021.
Among 195,989 Japanese adults followed a mean 4.61 years, higher quartiles of obesity–lipid indices were associated with 1.33–4.22-fold higher T2DM risk. AIP, CMI, and LAP showed the best discrimination (AUC 0.821–0.844), outperforming Mets-IR and TyG; predictive performance was stronger in participants <50 years and those with BMI <25 kg/m2.
Impact: Offers robust, population-scale validation of practical indices (AIP/CMI/LAP) for incident T2DM prediction, supporting risk stratification beyond BMI in East Asian adults.
Clinical Implications: Integrating AIP, CMI, or LAP into screening could identify high-risk individuals, particularly younger or non-obese adults, enabling earlier preventive interventions.
Key Findings
- In multivariable models, highest quartiles of indices conferred 1.33–4.22-fold higher T2DM risk vs lowest quartiles.
- AIP, CMI, and LAP achieved AUCs of 0.821–0.844, outperforming Mets-IR and TyG (0.756–0.780).
- Risk gradients were more pronounced in participants <50 years in both sexes.
- Predictive performance was higher among participants with BMI <25 kg/m2.
Methodological Strengths
- Very large longitudinal cohort (n=195,989) with mean 4.61-year follow-up.
- Multivariable Cox regression, sex- and age-stratified analyses, and ROC comparisons across indices.
Limitations
- Retrospective observational design with potential residual confounding and misclassification.
- External validation and clinical impact of index-guided interventions were not assessed.
Future Directions: Prospective validation, integration into clinical risk calculators, threshold optimization, and randomized trials of index-guided prevention strategies.
BACKGROUND: Obesity indices that combine anthropometric and lipid measurements, such as the atherogenic index of plasma (AIP), cardiometabolic index (CMI), lipid accumulation product (LAP), metabolic score for insulin resistance (Mets-IR), triglyceride-glucose (TyG) index, and visceral adiposity index (VAI), have been recommended as surrogates for assessing cardiometabolic risk. This study aimed to examine the association between these indices and type 2 diabetes mellitus (T2DM) incidence risk using lar